56 research outputs found
Glibenclamideâ10-h Treatment Window in a Clinically Relevant Model of Stroke
Glibenclamide improves outcomes in rat models of stroke, with treatment as late as 6 h after onset of ischemia shown to be beneficial. Because the molecular target of glibenclamide, the sulfonylurea receptor 1 (Sur1)-regulated NCCa-ATP channel, is upregulated de novo by a complex transcriptional mechanism, and the principal pathophysiological target, brain swelling, requires hours to develop, we hypothesized that the treatment window would exceed 6 h. We studied a clinically relevant rat model of stroke in which middle cerebral artery occlusion (75% < reduction in LDF signal â€90%) was produced using an intra-arterial occluder. Recanalization was obtained 4.5 h later by removing the occluder. At that time, we administered recombinant tissue plasminogen activator (rtPA; 0.9 mg/kg IV over 30 min). Immunolabeling showed modest expression of Sur1 5 h after onset of ischemia, with expression increasing 7- to 11-fold (Pâ<â0.01) by 24 h. Rats were administered either vehicle or glibenclamide (10 Όg/kg IP loading dose plus 200 ng/h by constant subcutaneous infusion) beginning 4.5 or 10 h after onset of ischemia. In rats treated at 4.5 or 10 h, glibenclamide significantly reduced hemispheric swelling at 24 h from (mean ± SEM) 14.7â±â1.5% to 8.1â±â1.6% or 8.8â±â1.1% (both Pâ<â0.01), respectively, and significantly reduced 48-h mortality from 53% to 17% or 12% (both Pâ<â0.01), and improved Garcia scores at 48 h from 3.8â±â0.62 to 7.6â±â0.70 or 8.4â±â0.74 (both Pâ<â0.01). We conclude that, in a clinically relevant model of stroke, the treatment window for glibenclamide extends to 10 h after onset of ischemia
Recommended from our members
Physiological responses during ascent to high altitude and the incidence of acute mountain sickness.
Acute mountain sickness (AMS) occurs when there is failure of acclimatisation to high altitude. The aim of this study was to describe the relationship between physiological variables and the incidence of AMS during ascent to 5300 m. A total of 332 lowland-dwelling volunteers followed an identical ascent profile on staggered treks. Self-reported symptoms of AMS were recorded daily using the Lake Louise score (mild 3-4; moderate-severe â„5), alongside measurements of physiological variables (heart rate, respiratory rate (RR), peripheral oxygen saturation (SpO2 ) and blood pressure) before and after a standardised Xtreme Everest Step-Test (XEST). The overall occurrence of AMS among participants was 73.5% (23.2% mild, 50.3% moderate-severe). There was no difference in gender, age, previous AMS, weight or body mass index between participants who developed AMS and those who did not. Participants who had not previously ascended >5000 m were more likely to get moderate-to-severe AMS. Participants who suffered moderate-to-severe AMS had a lower resting SpO2 at 3500 m (88.5 vs. 89.6%, p = 0.02), while participants who suffered mild or moderate-to-severe AMS had a lower end-exercise SpO2 at 3500 m (82.2 vs. 83.8%, p = 0.027; 81.5 vs. 83.8%, p 5000 m (OR 2.740, p-value 0.003) predicted the development of moderate-to-severe AMS. The Xtreme Everest Step-Test offers a simple, reproducible field test to help predict AMS, albeit with relatively limited predictive precision
Elevated intracranial pressure and cerebral edema following permanent MCA occlusion in an ovine model
INTRODUCTION: Malignant middle cerebral artery (MCA) stroke has a disproportionately high mortality due to the rapid development of refractory space-occupying cerebral edema. Animal models are essential in developing successful anti-edema therapies; however to date poor clinical translation has been associated with the predominately used rodent models. As such, large animal gyrencephalic models of stroke are urgently needed. The aim of the study was to characterize the intracranial pressure (ICP) response to MCA occlusion in our recently developed ovine stroke model. MATERIALS AND METHODS: 30 adult female Merino sheep (n = 8-12/gp) were randomized to sham surgery, temporary or permanent proximal MCA occlusion. ICP and brain tissue oxygen were monitored for 24 hours under general anesthesia. MRI, infarct volume with triphenyltetrazolium chloride (TTC) staining and histology were performed. RESULTS: No increase in ICP, radiological evidence of ischemia within the MCA territory but without space-occupying edema, and TTC infarct volumes of 7.9+/-5.1% were seen with temporary MCAO. Permanent MCAO resulted in significantly elevated ICP, accompanied by 30% mortality, radiological evidence of space-occupying cerebral edema and TTC infarct volumes of 27.4+/-6.4%. CONCLUSIONS: Permanent proximal MCAO in the sheep results in space-occupying cerebral edema, raised ICP and mortality similar to human malignant MCA stroke. This animal model may prove useful for pre-clinical testing of anti-edema therapies that have shown promise in rodent studies.Adam J. Wells, Robert Vink, Stephen C. Helps, Steven J. Knox, Peter C. Blumbergs, Renée J. Turne
Wykorzystanie popioĆu lotnego ze spalania w zĆoĆŒu z cyrkulacyjnÄ warstwÄ fluidalnÄ w zawiesinach twardniejÄ cych stosowanych w naprawach waĆĂłw przeciwpowodziowych
Strength and permeability properties along with microstructural evolution of hardened slurries composed of fly ash from fluidal bed combustion of brown coal and an addition of OPC/BFSC is assessed in this paper. An increase in the amount of fly ash in slurries influences the development of mechanical strength and a decrease of hydraulic conductivity. SEM, XRD, and porosity analyses confirmed formation of watertight microstructures. The structure of slurries is composed of ettringite, C-S-H phase, AFt, and AFm phases. Ettringite crystallises as relatively short needles forming compact clusters or intermixed with the C-S-H phase. The occurring C-S-H phases are mainly of type I â fibrous and type II â honeycomb.W artykule przedstawiono wyniki badaĆ wĆaĆciwoĆci mechanicznych, filtracyjnych oraz skĆadu fazowego i mikrostruktury zawiesin twardniejÄ
cych wykonanych z udziaĆem popioĆu lotnego z fluidalnego spalania wÄgla brunatnego po 28 i 90 dniach dojrzewania. Ten rodzaj popioĆu lotnego wykazuje siÄ wysokÄ
wodoĆŒÄ
dnoĆciÄ
, co ogranicza moĆŒliwoĆÄ jego wykorzystania w technologii betonu. Natomiast jego dodatek nie wpĆywa na wĆaĆciwoĆci zawiesiny twardniejÄ
cej ze wzglÄdu na duĆŒÄ
zawartoĆÄ wody. Zawiesiny wykonano wg trzech receptur w dwĂłch wariantach (po trzy prĂłbki na kaĆŒdÄ
recepturÄ, termin i rodzaj badania), w ktĂłrych popiĂłĆ lotny byĆ gĆĂłwnym skĆadnikiem spoiwa, a do niego dodano odpowiednio cement portlandzki CEM I 42,5 (prĂłbki 1-3) i cement hutniczy CEM III 32,5 (prĂłbki 4-6). Proporcje popioĆu do cementu byĆy nastÄpujÄ
ce: 1,81 (prĂłbki 1 i 4), 2,18 (prĂłbki 2 i 5), 2,45 (prĂłbki 3 i 6)
- âŠ